2
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Phase 2
1
Status
Recruiting
2
Sponsor Class
OTHER
1
INDUSTRY
1
Study Type
Interventional
2
Observational
1
Sponsor
Cancer Type
Thoracic
1
Myeloid
1
Classical hematology
1
Conditions
Venous Thromboembolism
1
Thrombocythemia, Essential
1
Primary Myelofibrosis
1
Polycythemia Vera
1
Hemorrhage
1
Carcinoma, Non-Small-Cell Lung
1
Interventions
Cyclophosphamide
3162
Cisplatin
3160
Carboplatin
2938
Paclitaxel
2673
Radiotherapy
2648
Gemcitabine
2547
pembrolizumab
2330
Docetaxel
2157
Bevacizumab
2128
Fluorouracil
1822
Capecitabine
1782
Oxaliplatin
1713
Dexamethasone
1590
Nivolumab
1517
Doxorubicin
1477
Rituximab
1454
Etoposide
1342
Magnetic Resonance Spectroscopy
1266
Irinotecan
1235
Leucovorin
1216
Cytarabine
1123
Pemetrexed
1062
Drug Therapy
1062
fludarabine
1050
Vincristine
956
Specimen Handling
935
Prednisone
925
Cetuximab
921
Lenalidomide
916
Trastuzumab
901
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Interventional
×
N(4)-oleylcytosine arabinoside
×
Clear all
NCT05498428
2026-05-08
PALOMA-2
Janssen Research & Development, LLC
Phase 2
Recruiting
520 enrolled
NCT05198960
2026-03-20
AVAJAK
University Hospital, Brest
Phase 3
Recruiting
1,308 enrolled